Drug Trial Radar · NCT06767150
StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Oct 2, 2025
Primary completion
Oct 2030
Study completion Oct 2030
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected increased risk of vertebral fractures. Defining the optimal strategy for Dmab withdrawal is critically needed. Investigator propose an open-label randomized superiority strategy trial to compare the 1-year lumbar densitometric efficacy of biomarkers-driven zoledronate (ZOL) infusion vs standardized ZOL treatment to mitigate rebound phenomenon.
Conditions
- Postmenopausal Osteoporosis
Interventions
a second infusion of ZOL when crosslaps levels reach 300 pg/mLDrug
a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start) and a second infusion when crosslaps levels reach 300 pg/mL, no later than month-12
a rescue second infusion at month-12 (standard traitment)Drug
a first infusion of ZOL 5 mg, 6 months after denosumab withdrawal (= study start), and potentially a rescue second infusion at month-12, in case unfavourable outcome (incident osteoporotic fractures) or high risk of unfavourable outcome
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maintain lumbar bone mineral density (BMD) after 1 year of ZOLTime frame: 1 year after inclusion
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Amiens Hospital
Amiens, France · Recruiting
Bordeaux Hospital
Bordeaux, France · Recruiting
Cahors Hospital
Cahors, France · Recruiting
Dax Hospital
Dax, France · Recruiting
Le Mans Hospital
Le Mans, France · Recruiting
Lille Hospital
Lille, France · Not yet recruiting
Limoges Hospital
Limoges, France · Recruiting
Marseille Hsopital
Marseille, France · Recruiting
Montpellier Hospital
Montpellier, France · Recruiting
Nice Hospital
Nice, France · Recruiting
Orléans Hospital
Orléans, France · Recruiting
Cochin Hospital
Paris, France · Recruiting
Lariboisiere Hospital
Paris, France · Recruiting
Poitiers Hospital
Poitiers, France · Recruiting
Rennes Hospital
Rennes, France · Recruiting
Saint Etienne Hospital
Saint-Etienne, France · Recruiting
Toulouse Hospital
Toulouse, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.